MammaTyper LRP score shows prognostic value in early luminal breast cancer

A new study in Clinical Breast Cancer found that the MammaTyper LRP score can help identify patients with early-stage luminal breast cancer who have a low risk of distant recurrence and may gain limited benefit from adjuvant chemotherapy. The retrospective analysis of 402 patients at Peking University First Hospital adds evidence for the assay’s role in more accessible risk stratification.

Why it matters: - The MammaTyper LRP score may help clinicians better separate early luminal breast cancer patients who need chemotherapy from those who may safely avoid it. - The study suggests the assay could support more individualized treatment decisions in a disease where endocrine therapy is standard but chemotherapy decisions remain difficult. - The findings may matter in markets where access to broader multigene assays is limited and lower-cost testing is a barrier to use.

What happened: - A study published in Clinical Breast Cancer found prognostic value for the MammaTyper LRP score in early-stage luminal breast cancer. - The research was led by Professor Ling Xu of Peking University First Hospital. - The retrospective study reviewed 402 patients treated at Peking University First Hospital between 2014 and 2018. - Patients had T1–2, N0–1 disease. - Median follow-up exceeded seven years.

The details: - LRP score was an independent prognostic factor in multivariable analysis, with an adjusted hazard ratio of 0.37. - Patients in the LRP low-risk group had a 9-year distant disease-free survival rate of 96.2%. - Patients in the LRP high-risk group had a 9-year distant disease-free survival rate of 87.0%. - The difference between the low-risk and high-risk groups was statistically significant, with HR=0.28 and p=0.0021. - Among patients classified as LRP low risk, 9-year distant disease-free survival was broadly comparable whether or not they received adjuvant chemotherapy. - The study’s authors said the result suggests the LRP score may identify patients with a favorable long-term prognosis. - Luminal breast cancer is generally ER and/or PR positive and HER2 negative. - Multigene expression assays can add biological information beyond clinicopathological factors. - Oncotype DX, a 21-gene assay, is widely used internationally in early-stage hormone receptor-positive, HER2-negative breast cancer. - Access to Oncotype DX remains limited in many parts of the world. - MammaTyper has previously shown the ability in direct comparative studies to identify low-risk patients with Oncotype DX Recurrence Score ≤25. - MammaTyper quantitatively measures HER2, ER, PR and Ki-67 using RT-qPCR techniques. - The company describes MammaTyper as a quick, accurate, reliable and reproducible assay. - The company says MammaTyper is the only assay of its type on the market backed by extensive data and research. - More information is available in the product page. - The study reference is Ding M, et al., "Clinical validation of the MammaTyper® LRP model for identification of low risk patients with early-stage ER+/HER2- breast cancer: from subtyping to chemotherapy de-escalation," published online Aug. 24, 2026.

Between the lines: - The study adds support for a lower-cost, locally available molecular test in settings where imported genomic assays can be expensive or hard to obtain. - The principal investigator said conventional clinicopathological factors alone have limits and can contribute to overtreatment. - The principal investigator said MammaTyper could become a broadly accessible multigene expression profiling tool for precision breast cancer treatment. - The study also reinforces a broader trend in breast cancer care toward de-escalating chemotherapy when molecular risk signals are favorable.

What's next: - The new data could push broader discussion of MammaTyper as an option for risk assessment in early luminal breast cancer. - The findings may influence how clinicians weigh chemotherapy for patients with low-risk molecular profiles. - Cerca Biotech continues to market MammaTyper across Germany, the Nordics, Eastern Europe, the Middle East, Africa, India and other regions.

The bottom line: - The Clinical Breast Cancer study gives MammaTyper LRP stronger clinical footing as a tool for identifying early luminal breast cancer patients who may be able to avoid unnecessary chemotherapy.